Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Jul 23, 2023
TickeronGET DAILY SIGNALS
Top Monthly Gainers: AI Robots Trading Stocks like $EVLO, $EDTX, & More

Top Monthly Gainers: AI Robots Trading Stocks like $EVLO, $EDTX, & More

AI Robots: Revolutionizing Trading Strategies in Every Style

Automated investment solutions are reshaping the financial landscape, and AI robots are leading this transformation. Advancements in artificial intelligence, machine learning, and big data analytics have enabled AI-powered trading robots to dominate the stock market with a myriad of trading styles, each adaptable to the evolving market trends.

Stock trading was once the purview of skilled professionals who could decipher intricate market signals. However, AI robots have democratized access to this realm, enabling all types of investors to capitalize on opportunities traditionally reserved for Wall Street gurus. And the recent market performance is proof of their effectiveness.

The power of these trading robots lies in their ability to sift through vast amounts of market data and pinpoint lucrative trading opportunities based on sophisticated algorithms. This capability is strikingly evident in the performance of some of the top gainers in the last month.

Consider the promising show by $EVLO, $EDTX, $EDTXU, $BDTX, $MLTX, $WULF, $GGAAU, $BBIO, $REKR, $SIRI. Stocks in this group exhibit a positive outlook, an evaluation backed by the Moving Average (MA) 200 and MA50 Indicator, a widely utilized tool in technical analysis.

The MA200MA50 Indicator is a well-established metric used by traders to gauge long-term and medium-term trends in the stock market. It works on a simple principle: when the 50-day moving average of a stock is above its 200-day moving average, it indicates a positive or bullish trend. On the contrary, if the 50-day moving average falls below the 200-day moving average, it signals a bearish trend.

However, for our analyzed stocks, the MA200MA50 Indicator has provided a positive outlook, signaling a bullish trend. It implies that the prices for these stocks have been generally increasing over the last 50 days compared to the previous 200 days. This bullish sentiment is a result of the precise algorithmic predictions of the AI robots that identified the potential for growth in these stocks.

As such, AI-powered trading robots have demonstrated their prowess in the stock market. They are capable of analyzing market trends, identifying profitable stocks, and trading in various styles that meet individual investors' needs. This kind of versatility, accuracy, and efficiency is pushing more investors to embrace these advanced trading tools.

The success of AI robots in trading is a testament to the rapid advancements in technology and its growing influence on the financial market. As they continue to evolve, there's little doubt that these AI-powered tools will solidify their place as indispensable aids in the world of stock trading, ushering in a new era of automated and more efficient investment strategies.

Related Ticker: BBIO, EVLO, EDTX, EDTXU, BDTX, MLTX, WULF, GGAAU, REKR, SIRI

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


BBIO in upward trend: price rose above 50-day moving average on October 28, 2026

BBIO moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend. In 43 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BBIO as a result. In 81 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

The 10-day moving average for BBIO crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBIO advanced for three days, in 248 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 188 of 208 cases where BBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The 10-day RSI Indicator for BBIO moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 23 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 64 cases where BBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.

The Moving Average Convergence Divergence Histogram (MACD) for BBIO turned negative on November 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 36 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

The 50-day moving average for BBIO moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

BBIO broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.774) is normal, around the industry mean (3.596). P/E Ratio (-20.868) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (18.587) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. BBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which engages in developing transformative medicines to treat patients who suffer from mendelian diseases.

Industry Biotechnology

Industry
N/A
Address
3160 Porter Drive
Phone
+1 650 391-9740
Employees
839
Web
https://www.bridgebio.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.